Dr. Rosen recalls the treatment options for patients diagnosed with B-cell lymphoma.
The treatment of B-cell lymphoma varies. In some instances, we’ll just observe the patient that there’s no evidence that an early intervention is indicated. In some instances, the patient may require chemotherapy, either very aggressive chemotherapy or chemotherapy that’s less toxic, and the most significant advances in the last decade have been in the area of biologic therapies, and these include agents such as antibodies, antibodies that actually target the lymphoma and kill the cells.
About Dr. Steven Rosen, M.D., F.A.C.P:
Steven Rosen, M.D., F.A.C.P., is Genevieve Teuton Professor of Medicine, at the Feinberg School of Medicine, Northwestern University and Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Director of Cancer Programs at Northwestern Memorial Hospital. Following his graduation with distinction from Northwestern University Medical School's Six-Year Honors Program in 1976, Dr. Rosen completed his residency in Internal Medicine at Northwestern and a fellowship in Medical Oncology at the National Cancer Institute. Dr. Rosen's laboratory research focuses on experimental therapeutics and hematologic malignancies.